| Objective:To investigate the relationship between plasma miRNA profile and early virological response (EVR) with interferon (or PEG-IFN) treatment in chronic hepatitis B using microarray and bioinformatics technology, in order to find novel biomarkers for prognosis.Methods:totally 94 cases (chronic hepatitis B) were enrolled, the training group consists of 66 patients who were treated with PEG-IFN a and test group consists of 28 patients treated with conventional IFN-α. Plasma was extracted from each patient at baseline and week 12, respectively. FFPE (formalin fixed paraffin embedded) liver tissues were also obtained in 13 of these patients. Plasma miRNA profiles were meaured by microarray; and quantity of miRNA was confirmed by real time RT-PCR. We also compared miRNA from liver tissues with that from plasma. Maximum Relevancy Minimum Redundancy (mRMR), incremental feature selection curve (IFS) Nearest Neighbor Algorithm (NN), Jackknife Cross-Validation, univariate and multivariate logistic regression analysis were used for statistical methods.Results:A predictor composed by 10 miRNA predicted early virology response accuracy 66.7% in training group, and 60.7% in test group. miRNAs profile in liver tissues and plasma expression showed high level of correlation in each individual (r=0.22-0.64 p= 0.013-4.7×10-15) and collectively (r=0.42, p<10-250), which suggested that miRNA level in plasma partially reflect that in liver tissues. Moreover, the 10 miRNA subset and pretreatment ALT were independent predictor factors for efficacy (univariate: OR=3.27,1.47, P=0.07,0.02; multivariate:OR=2.84,1.40, P=0.029,0.009)Conclusion:The 10 miRNAs subset in plasma may be a new biomarker as predictor for early virological response of IFN a or PEG-IFN a in chronic hepatitis B patients, which contribute in patient's compliance, increasing efficacy, avoiding adverse event, and can be a basis for personalized medicine. |
PDF Full Text Request